Bicycle Therapeutics plc
BCYCNASDAQHealthcare● Active
$4.23
+$0.03(+0.76%)
Market Cap$293663793
P/E Ratio—
52W High$9.36
52W Low$4.075
Bicycle Therapeutics plc (BCYC) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BCYC · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 30, 2026EPS Actual
-$0.87
Est. -$0.58 · -51.0%
Revenue
$0.00B
Est. $0.01B · -88.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 30, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
BCYC reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.40
Rev. $5.46B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.40
Rev. Est.$5.46B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 14, 2026 | -$0.58 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | Apr 30, 2026 | -$0.58 | -$0.87 | -51.0% | $0.00B | $0.01B | -88.2% |
| ▲ Q1 FY2026 | Mar 17, 2026 | -$0.94 | -$0.29 | +69.1% | $0.05B | $0.01B | +581.6% |
| ▲ Q4 FY2025 | Oct 30, 2025 | -$1.09 | -$0.85 | +22.0% | $0.01B | $0.01B | +65.8% |
| ▼ Q3 FY2025 | Aug 8, 2025 | -$0.95 | -$1.14 | -20.0% | $0.00B | $0.01B | -65.2% |
| ▼ Q2 FY2025 | May 1, 2025 | -$0.86 | -$0.88 | -2.3% | $0.01B | $0.01B | +8.0% |
| ▲ Q1 FY2025 | Feb 25, 2025 | -$0.85 | -$0.80 | +5.9% | $0.00B | $0.01B | -48.9% |
| ▲ Q4 FY2024 | Oct 31, 2024 | -$0.78 | -$0.74 | +5.1% | $0.00B | $0.01B | -56.9% |
Q3 FY2026
Aug 14, 2026
EPS Actual
—
EPS Est.
-$0.58
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 30, 2026Miss
EPS Actual
-$0.87
EPS Est.
-$0.58
EPS Surpr.
-51.0%
Revenue
$0.00B
Q1 FY2026
Mar 17, 2026Beat
EPS Actual
-$0.29
EPS Est.
-$0.94
EPS Surpr.
+69.1%
Revenue
$0.05B
Q4 FY2025
Oct 30, 2025Beat
EPS Actual
-$0.85
EPS Est.
-$1.09
EPS Surpr.
+22.0%
Revenue
$0.01B
Q3 FY2025
Aug 8, 2025Miss
EPS Actual
-$1.14
EPS Est.
-$0.95
EPS Surpr.
-20.0%
Revenue
$0.00B
Q2 FY2025
May 1, 2025Miss
EPS Actual
-$0.88
EPS Est.
-$0.86
EPS Surpr.
-2.3%
Revenue
$0.01B
Q1 FY2025
Feb 25, 2025Beat
EPS Actual
-$0.80
EPS Est.
-$0.85
EPS Surpr.
+5.9%
Revenue
$0.00B
Q4 FY2024
Oct 31, 2024Beat
EPS Actual
-$0.74
EPS Est.
-$0.78
EPS Surpr.
+5.1%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-1.17 | $-0.63 | $-0.28 | 2 |
| Q3 FY2027 | $-1.14 | $-0.62 | $-0.27 | 2 |
| Q2 FY2027 | $-1.12 | $-0.61 | $-0.27 | 2 |
| Q1 FY2027 | $-1.11 | $-0.60 | $-0.26 | 2 |
| Q4 FY2026 | $-0.70 | $-0.38 | $-0.17 | 4 |
| Q3 FY2026 | $-0.54 | $-0.50 | $-0.45 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Apr 30, 2026 | -51.0% | $4.73 | $4.72 | -0.21% |
| ▲ Q1 FY2026 | Mar 17, 2026 | +69.1% | $5.05 | $5.07 | +0.40% |
| ▲ Q4 FY2025 | Oct 30, 2025 | +22.0% | $8.18 | $8.76 | +7.09% |
| ▼ Q3 FY2025 | Aug 8, 2025 | -20.0% | $7.46 | $7.65 | +2.55% |
| ▼ Q2 FY2025 | May 1, 2025 | -2.3% | $8.56 | $9.08 | +6.07% |
| ▲ Q1 FY2025 | Feb 25, 2025 | +5.9% | $11.25 | $11.10 | -1.33% |
| ▲ Q4 FY2024 | Oct 31, 2024 | +5.1% | $24.03 | $23.45 | -2.41% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +30.0% | $22.71 | $24.38 | +7.35% |
Q2 FY2026-0.21%
Report Date
Apr 30, 2026
EPS Beat/Miss
-51.0%
Price Before
$4.73
Price After
$4.72
Q1 FY2026+0.40%
Report Date
Mar 17, 2026
EPS Beat/Miss
+69.1%
Price Before
$5.05
Price After
$5.07
Q4 FY2025+7.09%
Report Date
Oct 30, 2025
EPS Beat/Miss
+22.0%
Price Before
$8.18
Price After
$8.76
Q3 FY2025+2.55%
Report Date
Aug 8, 2025
EPS Beat/Miss
-20.0%
Price Before
$7.46
Price After
$7.65
Q2 FY2025+6.07%
Report Date
May 1, 2025
EPS Beat/Miss
-2.3%
Price Before
$8.56
Price After
$9.08
Q1 FY2025-1.33%
Report Date
Feb 25, 2025
EPS Beat/Miss
+5.9%
Price Before
$11.25
Price After
$11.10
Q4 FY2024-2.41%
Report Date
Oct 31, 2024
EPS Beat/Miss
+5.1%
Price Before
$24.03
Price After
$23.45
Q3 FY2024+7.35%
Report Date
Aug 6, 2024
EPS Beat/Miss
+30.0%
Price Before
$22.71
Price After
$24.38
Avg Beat Reaction+2.22%
Avg Miss Reaction+2.80%
Beat Rate5 / 8 quarters
Largest Move+7.35% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BCYC ends December
Bicycle Therapeutics plc (BCYC) most recently reported earnings on April 30, 2026 for Q2 FY2026, posting EPS of $-0.87 — missing the analyst consensus of $-0.58 by -51.0%. The next BCYC earnings date is expected around September 1, 2026.
Each quarter, investors track BCYC earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BCYC revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BCYC's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BCYC earnings · 5 questionsBicycle Therapeutics plc's next earnings report is expected around September 1, 2026. BCYC typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BCYC historically reports after market close (AMC).
BCYC earnings datewhen is BCYC earningsBCYC next earnings datewhen does BCYC report earningsBCYC earnings calendar
▸ Source: FMP · Bicycle Therapeutics plc SEC filings · US GAAP · Bicycle Therapeutics plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026